EEEkene A. Enemchukwu

Ekene A. Enemchukwu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ekene A. Enemchukwu has a total of 122 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Perspectives of Older Adults on Digital Health Interventions for Overactive Bladder: A Pre-Implementation Qualitative Study

    by Susanna Gunamany, Melissa Dzinoreva, Shada Sinclair, Hodan Mohamud, Victoria Harbour, Ekene Enemchukwu

  • Open Access

    Cost‐effectiveness and patient‐reported outcomes of combined versus isolated robotic rectal and pelvic organ prolapse repair: A multicentre prospective cohort study

    by Shannon L. Wallace, James W. Ogilvie, Liliana Bordeianou, Michelle Earley, Raisa Platte, Milena M. Weinstein, Eric R. Sokol, Ekene A. Enemchukwu, Kavita Mishra, Brooke H. Gurland

    Aim: Rectal prolapse (RP) and pelvic organ prolapse (POP) frequently coexist, yet are often evaluated and treated separately. This study aimed to compare patient‐reported outcomes and cost‐effectiveness of combined versus isolated robotic prolapse repair. Methods: We conducted a prospective multicentre cohort study across three tertiary pelvic floor centres. Women undergoing robotic rectal prolapse repair (rRP), robotic pelvic organ prolapse repair (rPOP) or combined robotic repair (rRP + rPOP) were included. Validated patient‐reported outcome measures were collected at baseline and 12 months. Health utility was derived from EQ‐5D‐3L and used to calculate quality‐adjusted life years (QALYs). A trial‐based cost‐effectiveness analysis was performed from the healthcare sector perspective. A theoretical cohort was modelled to examine staged versus combined repair in patients with multicompartment prolapse. Results: Forty‐seven patients were included (rRP n = 14, rPOP n = 16, rRP + rPOP n = 17). All groups demonstrated significant improvement in pelvic floor symptoms and quality of life at 12 months. Improvements across bowel, bladder and prolapse‐related domains were greatest in the combined repair group. Health utility gains were observed in all cohorts. In patients with multicompartment prolapse, combined robotic repair was cost‐effective, whereas staged procedures were associated with higher cumulative costs without proportional gains in QALYs. Conclusions: Within robotic prolapse surgery, combined rectal and pelvic organ prolapse repair provides the most comprehensive symptom improvement and represents a cost‐effective strategy when both compartments are symptomatic. These findings support systematic evaluation for multicompartment prolapse and multidisciplinary surgical planning.

  • Open Access

    Health Disparities and Overactive Bladder: Bridging the Gap

    by Susanna Gunamany, Angeleque Hartt, Rachel Kopkin, Ibukunowola Omole, Ekene A. Enemchukwu

    Purpose of the Review Overactive bladder (OAB) affects ~ 33 million Americans. Most studies enroll predominantly educated, non-Hispanic White women, limiting understanding of how social determinants, race/ethnicity, and structural inequities influence OAB burden and treatment. Evidence suggests disparities in prevalence, diagnosis, and guideline-based therapy reflect social and structural factors rather than biology. Recent Findings Literature from 2010 to 2025 notes higher OAB burden among Black, Hispanic, and lower-income women. Structural barriers (e.g., limited specialist access, high costs, restrictive insurance, and competing needs) reduce care-seeking and therapy adherence. Social and cultural factors, including stigma, mistrust, low health literacy, and language barriers, further limit engagement. Minority and low-income patients utilize pharmacologic and minimally invasive therapies less frequently despite greater symptom severity. Frailty affects treatment selection but does not appear to impact benefit. Strategies to address disparities include inclusive research, culturally tailored education, digital and community-based care, and patient navigators. Summary OAB disparities reflect intersecting structural, socioeconomic, and cultural factors. Equity requires inclusive research, responsive education, expanded access, and policy reform to address structural determinants.


  • Open Access

    Vaginal Estrogen Utilization Among Medicare Beneficiaries With Genitourinary Syndrome of Menopause

    by Kelsey Gallo, Chiyuan Amy Zhang, Claire Burton, Neil Kamdar, Ekene A. Enemchukwu

    Importance: Low-dose vaginal estrogen (VE) is a safe and effective treatment for genitourinary syndrome of menopause (GSM). The frequency of VE prescribing for GSM is unknown. Objective: To evaluate VE prescriptions among women with GSM and to identify clinical phenotypes associated with VE claims. Design, Setting, and Participants: This is a retrospective, population-based cohort study of a 20% random sample of Medicare fee-for-service beneficiaries enrolled in Parts A, B, and D from 2006 to 2018. Women aged 66 years and older with a diagnosis indicative of GSM were included. Exclusion criteria included diagnoses of breast and/or endometrial cancer within 6 months of GSM diagnosis. Data analysis was performed from October 2023 to June 2024. Exposure: Diagnosis indicative of GSM. Main Outcomes and Measures: The primary outcome was the proportion of women with a VE prescription claim (cream, ring, or tablet) during the follow-up period, from first GSM diagnosis to the end of Medicare enrollment or the study period. To quantify associations between patient characteristics and the likelihood of VE claims, univariable and multivariable logistic regression analyses were conducted. Results: A total of 1 838 732 women with at least 1 GSM-related diagnosis were identified (median [IQR] age, 74 [69-81] years; median [IQR] follow-up, 8 [4-10] years). VE prescriptions were filled by 165 530 women (9.0%) at a median (IQR) of 15 (2-46) months after diagnosis. Older women (adjusted odds ratio [aOR] for >86 years vs 66-70 years, 0.59; 95% CI, 0.58-0.60) and those with higher Charlson Comorbidity Index scores (aOR for score ≥5 vs 0, 0.67; 95% CI, 0.66-0.69) were less likely to have a VE claim. When comparing GSM symptom groups, women with recurrent urinary tract infections were least likely to have a VE claim (aOR vs local sexual symptoms, 0.54; 95% CI, 0.46-0.64). Women with vulvovaginal symptoms (aOR, 2.70; 95% CI, 2.45-2.97) and GSM multimorbidity (aOR, 15.91; 95% CI, 14.41-17.57) were most likely to have a VE claim. Conclusions and Relevance: In this large cohort study, 9.0% of female Medicare beneficiaries with a diagnosis indicative of GSM filled a VE prescription. Younger and healthier beneficiaries and those with GSM multimorbidity were more likely to fill a VE prescription. The majority of patients with GSM symptoms, including dyspareunia, vulvovaginal atrophy, and recurrent urinary tract infections, did not fill a VE prescription. Improving patient and practitioner education, revising the diagnostic code schema to capture the full breadth of symptoms, and validating GSM clinical phenotypes will help facilitate care and enhance our understanding of symptoms in research studies.


  • Open Access

    The Impact of Patient Navigators on Overactive Bladder Care: Real-World Practice Patterns from a US National Database

    by Ekene Enemchukwu, Jennifer Miles-Thomas, Nitya Abraham, Diane K. Newman, Marc Schwartz, Kimberly Becker Ifantides, Mariana Nelson, Raveen Syan

    Background/Objectives: We here describe the impact of navigated care on utilization patterns of pharmacologic and minimally invasive overactive bladder therapies. Methods: This retrospective observational cohort study used electronic medical record data from the Precision Point Specialty Analytics Portal in the United States. Eligible patients were adults (≥18 years) newly diagnosed and treated for non-neurogenic overactive bladder (1 January 2015 to 31 December 2019). Categorical endpoints were analyzed by chi-square test or Fisher exact test. Of 170,000 eligible patients, 8982 (≈5%) were randomly selected and stratified by navigation status (navigated: 1150 [12.8%]; non-navigated: 7832 [87.2%]). Results: Overall, 60.0% of patients were female, 69.9% were White, and 42.7% had Medicare coverage. Navigated care was more common among women, Black patients, and those covered by Medicaid/Medicare. Initial pharmacologic treatment rates were similar between navigated and non-navigated groups (anticholinergic: 57.0% vs. 57.4%; beta-3 agonist: 43.0% vs. 42.6%). Greater percentages of navigated versus non-navigated patients received minimally invasive therapy (23.8% vs. 10.8%, respectively; p < 0.0001). Discontinuation rates were lower for navigated versus non-navigated patients undergoing pharmacologic treatment (62.5% vs. 71.3%; p < 0.0001). Conclusions: Patient navigation for overactive bladder may help increase access to minimally invasive therapies and may be a tool to address treatment disparities.


  • Open Access

    Multidisciplinary conferences to enhance care for pelvic floor dysfunction: A descriptive study at a tertiary center

    by Nouf Yahya Akeel, Leila Neshatian, Vipul Sheth, Ekene Enemchukwu, Sydni Au Hoy, Brooke H. Gurland, Diana Atashroo, Yosef Chodakiewitz, Jimmy Dinh, Haddas Elisha, et al.

  • Open Access

    Intravesical Onabotulinum Toxin A Injection Paradigms for Idiopathic Overactive Bladder: A Scoping Review of Clinical Outcomes, Techniques, and Implications for Practice and Future Research

    by Ekene Enemchukwu, Hodan Mohamud, Shada Sinclair, Victoria Harbour, Raveen Syan, Michael Kennelly, Susanna Gunamany

    Introduction and Objectives: Onabotulinum toxin A (BTXA) is an effective treatment for refractory idiopathic overactive bladder (iOAB). Given the wide spectrum of patient factors and combination of symptoms, a tailored approach to management is needed. This scoping review assesses injection paradigms for iOAB. Prior studies have established the safety and efficacy of BTXA injections, and this review focuses on exploring variations in injection techniques that may inform more tailored approaches and support future research toward optimizing patient outcomes. Methods: We conducted a systematic literature search. Inclusion criteria included full-text English language and primary research studies assessing outcomes in adults undergoing BTXA for iOAB. Findings are summarized using narrative synthesis. Results: Forty-three articles were identified. Key findings include fewer injections (1–10 vs. 20–40) maintains efficacy while reducing procedure time, discomfort, and retreatment hesitancy. Durability appears to be lower with suburothelial and bladder base injections and higher with detrusor and bladder body injections, though these may carry an increased risk of urinary retention requiring clean intermittent catheterization. Trigone inclusion appears safe and effective without increased vesicoureteral reflux risk. Conclusions: Study heterogeneity and inconsistent reporting limit strong conclusions. Included injection paradigms demonstrated efficacy, high tolerability, symptom relief, and quality-of-life improvements with few adverse events. Further research is needed to refine optimal injection strategies to enhance patient comfort, maximize efficacy, and minimize adverse events. Future studies should ensure comprehensive data collection to clarify these associations.


  • Open Access

    Gene Therapy With URO-902 (pVAX/ hSlo ) for the Treatment of Female Patients With Overactive Bladder and Urge Urinary Incontinence: Safety and Efficacy From a Randomized Phase 2a Trial

    by Ekene A. Enemchukwu, Susan Kalota, Kaiser Robertson, Sijian Ge, Jingmei Lu, Hanh Badger, Salim Mujais, Kenneth M. Peters

    We assessed efficacy and safety of URO-902, an investigational gene therapy expressing the α subunit of the large-conductance Ca2+-activated K+ channel, in a phase 2a placebo-controlled trial in women with overactive bladder (OAB). Women, age 40 to 79 years, with OAB and urge urinary incontinence who were refractory to OAB medications were randomized to single-dose URO-902 24 and 48 mg or placebo administered by intradetrusor injection via cystoscopy under local anesthesia. Efficacy end points included change from baseline to week 12 in mean daily micturitions, urgency episodes, urge urinary incontinence episodes, and patient-reported outcomes. Safety assessments included adverse events and postvoid residual urine volume. Of 80 patients randomized (URO-902 24 mg, n = 26; URO-902 48 mg, n = 27; placebo, n = 27), 74 received treatment, and 67 reached week 24. At week 12, URO-902 24 and 48 mg were associated with significant improvement vs placebo in daily micturitions (least-squares mean change from baseline, -2.3 and -2.4 vs -0.8, respectively; least-squares mean difference [95% CI], ‒1.5 [‒2.7 to ‒0.3] and ‒1.6 [‒2.8 to ‒0.4], nominal P = .017 and P = .009, respectively). URO-902 48 mg was associated with significant improvements vs placebo in urgency episodes (‒3.4 vs ‒1.1; ‒2.2 [‒4.0 to ‒0.4]; nominal P = .016) and percentage of Patient Global Impression of Change responders (58% vs 31%; nominal P = .026). Among patients receiving URO-902 24 mg, URO-902 48 mg, and placebo, 46%, 54%, and 54%, respectively, experienced ≥ 1 treatment-emergent adverse events, most commonly UTI (0%, 15%, 4%) and hematuria (6%, 8%, 8%). In this phase 2a trial, treatment with URO-902 was associated with improvements vs placebo in efficacy and patient-reported outcomes and was safe and well tolerated.


  • Trends in Overactive Bladder Therapy: Associations Between Clinical Care Pathways, Practice Guidelines, and Therapy Utilization Patterns

    by Hodan Mohamud, Shada Sinclair, Susanna Gunamany, Claire S. Burton, Chiyuan A. Zhang, Raveen Syan, Ekene A. Enemchukwu

    Introduction: Overactive bladder (OAB) is a chronic condition with significant financial and health‐related consequences. Guidelines and treatment pathways were created to optimize care and provide a clinical framework for diagnosing and managing OAB. However, the impact of these efforts and patterns of medical treatment for OAB are poorly understood. Therefore, we sought to evaluate overall trends in therapy utilization before and after the 2014 American Urological Association (AUA)/Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) OAB guideline amendment and publication of the OAB clinical care pathway in 2016.Methods: In this retrospective cohort study, we analyzed data from Optum, a national administrative health and pharmacy claims database, between 2013 and 2018. All adult patients diagnosed with idiopathic OAB were identified by the International Classification of Diseases 9th and 10th Revision codes. Oral OAB therapies were identified using National Drug Codes, while third‐line therapy procedures, onabotulinumtoxinA (BTX), sacral neuromodulation (SNM), and percutaneous tibial nerve stimulation (PTNS), were identified using Current Procedural Terminology (CPT) codes. The study's primary outcome was the annual number of OAB prescriptions filled by pharmacotherapy class and the number of minimally invasive therapies performed during the study period. The secondary outcome was the association between OAB therapy utilization and various clinical and sociodemographic factors. Patterns of care were analyzed from 2013 to 2018, and initial treatment with each therapy was collected, excluding repeat procedures from the analysis.Results: 1 825 782 patients were included in the study. The mean age was 61.1 ± 16.7 years, and 1 071 420 patients were female (58.7%). The number of new OAB diagnoses increased by 369% from 2013 to 2017. During the 6‐year study period, 347 052 (19%) patients were treated with oral and/or third‐line therapies. The overall number of oral medications prescribed peaked in 2016, followed by a 17% decline between 2016 and 2018. In 2013, the two most prescribed oral medications were oxybutynin (46%) and solifenacin (31.8%). By 2018, mirabegron (18.5%) surpassed solifenacin (16.5%), with oxybutynin still accounting for most prescriptions written (55%). Eighty percent of all initial mirabegron prescriptions were filled by patients over the age of 65. The rate of third‐line therapy procedures almost doubled between 2013 and 2018 (9–17 procedures per 1000 OAB patients, p < 0.001).Conclusions: Following the publication of the first OAB guidelines, there was an increase in OAB diagnoses, followed by a decrease in anticholinergic medication use, and a rise in beta‐3 agonist utilization in patients over 65 years old. Additionally, there was greater adoption of third‐line OAB therapies. These trends indicate that OAB therapy guidelines and clinical practice pathways may influence treatment patterns. Given the recent publication of the OAB guidelines, further studies are necessary to assess their impact on therapy utilization patterns.